Disease Domain | Count |
---|---|
Nervous System Diseases | 2 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 1 |
Recombinant polypeptide | 1 |
Growth factors | 1 |
Target |
Mechanism SYNGAP1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism MAS1L agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism 5-LOX inhibitors |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseWithdrawn |
First Approval Ctry. / Loc. US |
First Approval Date04 Sep 1992 |
Start Date09 Feb 2025 |
Sponsor / Collaborator |
Start Date22 Jun 2023 |
Sponsor / Collaborator |
Start Date01 Oct 2021 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Peptide therapeutics(The University of Arizona Health Network) ( MAS1L ) | Cognition Disorders More | Phase 2 |
Perillyl alcohol ( SYNGAP1 ) | Actinic Keratosis More | Phase 2 |
Keratinocyte growth factor(The University of Arizona Health Network) | Alopecia More | Phase 1 |
Masoprocol ( 5-LOX ) | Actinic Keratosis More | Withdrawn |
Melanotan II ( melanocortin receptor ) | Erectile Dysfunction More | Discontinued |